

# Ebstein's anomaly in children and adults: multidisciplinary insights into imaging and therapy

Giulia Pasqualin (), <sup>1,2</sup> Antonio Boccellino, <sup>3</sup> Massimo Chessa (), <sup>1,2,4</sup> Giuseppe Ciconte (), <sup>3,4</sup> Cecilia Marcolin, <sup>4</sup> Emanuele Micaglio (), <sup>3</sup> Carlo Pappone (), <sup>3,4</sup> Francesco Sturla (), <sup>5,6</sup> Alessandro Giamberti<sup>7</sup>

#### ABSTRACT

therapeutic strategy.

► Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi. org/10.1136/heartjnl-2023-322420).

For numbered affiliations see end of article.

#### Correspondence to

Dr Giulia Pasqualin, Pediatric and Adult Congenital Disease Heart Centre, IRCCS Policlinico San Donato, San Donato Milanese, Italy; Giulia.Pasqualin@ grupposandonato.it

Received 16 January 2023 Accepted 20 June 2023 Published Online First 24 July 2023

#### Check for updates

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Pasqualin G, Boccellino A, Chessa M, *et al. Heart* 2024;**110**:235–244. Although survival has significantly improved in the last four decades, the diagnosis of Ebstein's anomaly is still associated with a 20-fold increased risk of mortality, which generally drops after neonatal period and increases subtly thereafter. With increasing age of presentation, appropriate timing of intervention is challenged by a wide spectrum of disease and paucity of data on patient-tailored interventional strategies. The present review sought to shed light on the wide grey zone of post-neonatal Ebstein's manifestations, highlighting current gaps and achievements in knowledge for adequate risk assessment and appropriate

A 'wait-and-see' approach has been adopted in many circumstances, though its efficacy is now questioned by the awareness that Ebstein's anomaly is not a benign disease, even when asymptomatic. Moreover, older age at intervention showed a negative impact on postsurgical outcome.

In order to tackle the extreme heterogeneity of Ebstein's anomaly, this review displays the multimodality imaging assessment necessary for a proper anatomical classification and the multidisciplinary approach needed for a comprehensive risk stratification and monitoring strategy. Currently available predictors of clinical outcome are summarised for both operated and unoperated patients, with the aim of supporting the decisional process on the choice of appropriate therapy and optimal timing for intervention.

# FROM BENCH TO BEDSIDE Embriology and anatomy

Ebstein's anomaly (EA) is a congenital valvular and ventricular dysplasia of the right-sided heart, frequently associated with left-sided heart anomalies.<sup>1 2</sup> EA results from incomplete delamination of the tricuspid valve (TV) from the right ventricular (RV) endocardium, which occurs between the 7th and 12th week of intrauterine life.<sup>3</sup> During this process, the innermost layer of the ventricular wall separates from the underlying tissue, forming TV leaflets and tendinous chordae. Genetics and environmental factors supposed to be involved in EA pathogenesis are provided in online supplemental material (section A, table 1).

Impaired fibrous transformation from the muscular precursor results in adherence of TV components to the RV wall, thus causing an apical displacement of the septal leaflet (SL) hinge point.<sup>1</sup>

The same pathological process may involve the posterior leaflet (PL) while less frequently the anterior leaflet (AL), due to a supposed different embryology.<sup>1 3</sup> Leaflets may adhere to the endocardium either directly, through linear (figure 1A, C and D; online supplemental video 1) or focal attachments (online supplemental ideo 2), or indirectly, through accessory fibrous chordae or muscular stumps (figure 1C and D; Online supplemental video 1).<sup>1</sup>

Leaflets adherence to RV wall determines two key EA anatomopathological features: (1) the TV effective orifice separates from the anatomical annulus and rotates towards the right ventricular outflow tract (RVOT) of a degree which depends on the extension of the delamination defect (figure 1C and D)<sup>4</sup>; (2) the myocardial wall above the effective TV orifice is 'atrialized' (figure 1A, C and D), thus rendering EA a 'RV myopathy' beyond a valve disease.<sup>15</sup>

The atrialized RV (aRV) lacks of myocardial fiber concentration and presents reduced wall thickness (figure 1A, C and D). The part of RV responsible for stroke volume (SV) generation is the functional RV (fRV), which extends from the effective TV orifice to the pulmonary valve (figure 1B, C and D).<sup>15</sup> The combination of aRV and fRV identifies the anatomical RV (ARV).

#### Multimodality imaging

The quantitative criterion for EA diagnosis is an apical displacement of the SL hinge point by at least 8 mm/m<sup>2</sup> from the anterior mitral leaflet insertion, assessed in four-chamber view<sup>1 6</sup> (figure 1B). An absolute distance in atrioventricular valves offsetting of 15 mm in children and 20 mm in adults is also considered diagnostic.<sup>7</sup> Multimodality imaging is pivotal not only for anatomical and functional assessment of TV and right-sided chambers but also for identifying associated lesions (online supplemental material, section B

Transthoracic echocardiography (TTE) is usually the first diagnostic tool. Second-line imaging includes transoesophageal echocardiography (TOE) and cardiovascular magnetic resonance (CMR), the former with particular usefulness in TV assessment, the latter in right-sided chamber volumes calculation and myocardial characterization. CMR is superior to TTE in the detection of PL and extracardiac abnormalities, while TTE reveals small septal communications more frequently.<sup>6</sup> Echocardiography and CMR are both recommended for





# Tricuspid valve leaflets: \* Anterior \* Septal \* Posterior

**Figure 1** Magnetic resonance cine-SSFP images in a patient with Ebstein's anomaly in short axis (A, B) and long axis (C, D) views at end-diastole, highlighting the orientation of each cine-SSFP slice. Focusing on the tricuspid valve, apical displacement of the septal leaflet and rotation angle are reported in horizontal long-axis (C) and vertical long-axis views (D), respectively. RV, right ventricle; SSFP, steady-state free precession .

evaluating unoperated patients, informing on progressive disease and anatomies suitable of repair, as well as for monitoring operated patients, revealing surgical results and possible complications (figure 2).<sup>8 9</sup>

TOE is the fundamental imaging technique in the operation theatre. Cardiac computed tomography may be considered instead of CMR in cases of contraindications or major artefacts in the magnetic field, as well as before planning redo surgeries or 'valve-in-valve' replacements.

Over time, various classifications of EA severity had been proposed (figure 3). In patients older than 10 years, the CMR-derived total right/left-volume index showed higher association with clinical decompensation compared with Celermajer index and fRV to left ventricle (LV) ratio (figure 3), but revealed no correlation with the occurrence of major cardiovascular events (MACEs).<sup>10-12</sup> Imaging parameters predictive of adverse outcome in EA are reported in online supplemental tables 2 and 3.

## Tricuspid valve

TV is usually incompetent in EA, being occasionally stenotic.<sup>1</sup> Failure of delamination is responsible for a restrictive movement

of the affected leaflet or its functional absence (online supplemental videos 1 and 2).<sup>16</sup> AL may present fenestrations which contribute to tricuspid regurgitation (TR) as well as fibromuscular attachments which cause RVOT obstruction.<sup>16</sup>

Comprehensive echocardiographic examination relies on multiple TV views, often obtained by tilting the TTE probe from conventional axis (figure 4) or adapting the TOE transducer to different orientations (online supplemental figure 1).

CMR allows a cross-reference between short-axis and long-axis views in the post-processing analysis, as illustrated in figure 1. Cine steady-state free precession (cine-SSFP) and gradient-echo sequences are used to evaluate TV leaflets' morphology and motion. During a CMR examination, SL is detectable along the IVS. The other leaflets are visualised along the free wall: in a short-axis stack, PL is located next to the inferior wall and AL is adjacent to the lateral wall, while, in a para-axial stack from the diaphragm to the semilunar valves, PL and AL are detectable in bottom and top slices respectively (online supplemental figure 2). A vertical RV long-axis view explores both RV inflow and outflow, allowing the evaluation of PL delamination defects and possible RVOT obstruction; additionally, the degrees of



**Figure 2** Cone repair assessed through multimodality imaging during diastole (A): vertical long axis view of cine-SSFP sequence from CMR imaging and en face view by 3D-TOE (ventricular perspective). White arrows indicate the cone-shaped valve. (B) Structural complications of cone repair, as highlighted by a white arrow: (I) en face neo valve view with dehiscence of the antero-septal region by colour flow Doppler 3D-TOE; (II) phase-sensitive inversion recovery reconstruction (PSIR) sequence of a mid-ventricular short-axis view, showing myocardial infarction in the territory supplied by the right coronary artery, as represented by transmural late gadolinium enhancement of the inferior wall, inferior septum and RV diaphragmatic wall; (III) cine-SSFP mid-ventricular short-axis view of right ventricular plication dehiscence; (V) colour flow Doppler 2D TTE of neo-subvalvular acceleration in a four-chamber view. CMR and TTE images are courtesy of Boston Children's Hospital, Department of Cardiology. CMR, cardiovascular magnetic resonance; 3D-TOE, three-dimensional transesophageal echocardiography; RV, right ventricle; SSFP, steady-state free precession; TTE, transthoracic echocardiography.

the effective TV orifice rotation can be quantified in this view (figure 1D).<sup>4</sup>

An 'en face' reconstruction of TV is retrievable from multiple long-axis views using three-dimensional (3D) TTE (online supplemental video 3) and TOE (online supplemental figure 1).

In mild disease, the TV offset from the anatomical annulus is modest and multimodal TR quantification is based on current recommendations. In case of significant TV orifice rotation from the anatomical annulus, regurgitant jets are generally better appreciated in long-axis rather than short-axis views. In these settings, TR echocardiographic evaluation is often qualitative, while CMR-based quantification is possible by subtracting total pulmonary antegrade flow from RV SV rather than using through-plane phase-contrast sequences orthogonal to the TV annulus.

TR is proportionally associated with decreased functional capacity in unoperated patients and its progression is accompanied by right-sided chambers volume overload and decreasing proportion of the left-sided chambers.<sup>11 13</sup>

#### **Right atrium**

RA is typically enlarged in EA and presents decreased either reservoir, conduit and booster pump function.<sup>14</sup> Fibrosis is predominantly observed in the free wall and showed an association with atrial tachycardia onset.<sup>15</sup> RA function is impaired in EA patients with heart failure (HF) and progressive disease.<sup>14 16</sup>

#### **Right Ventricle**

Although variability exists among different EA severity grades (figure 3), fRV is frequently enlarged and presents reduced systolic function when compared with normal subjects.<sup>14 17</sup> Differently from echocardiographic techniques, CMR allows an unrestrictive view on right-sided heart chambers. In volume quantification, the para-axial cine-SSFP stack boundaries tracking showed a higher reproducibility than short-axis cine-SSFP stack (online supplemental figure 2).<sup>18</sup> Late gadolinium enhancement is typically revealed in the site of TV leaflet delamination defects.<sup>15</sup>

In regard to fRV function, the transverse rather than longitudinal component of contraction proved to be predominantly impaired in unoperated EA, even in the presence of preserved ejection fraction (EF).<sup>17</sup>

In general, data related to right-sided heart volumes mainly reflect cardiac decompensation and increased arrhythmic risk.<sup>11 12 14</sup> Specifically, aRV volume proved to be a marker of exercise intolerance and QRS fractionation, which is a known predictor of arrhythmic events.<sup>13 19 20</sup> Concomitantly, indexes of fRV systolic function revealed an association with MACEs, as detailed in online supplemental table 2.<sup>12 16</sup>

#### Left ventricle

The evidence that biventricular systolic impairment confers a ninefold increase in the risk of MACEs enlightens the impact of EA on left-sided heart.<sup>12</sup>



**Figure 3** Classification of Ebstein's anomaly from imaging. For the quantitative indexes, each term of the formula is highlighted in yellow when it is part of the numerator and in red when it is part of the denominator. AL, anterior leaflet; aRV, atrialised right ventricle; CMR, cardiac magnetic resonance; fRV, functional right ventricle; LA, left atrium; LV, left ventricle; PL, posterior leaflet; RA, right atrium; RV, right ventricle; SL, septal leaflet; TTE, transthoracic echocardiography.

When compared with healthy subjects, LV shows reduced volumes, systolic and diastolic function.<sup>14 21 22</sup> LV impairment in EA is multifactorial and principally triggered by: (1) interventricular dependency (aRV–LV and fRV–LV interaction); (2) reduced LV preload due to decreased forward RV SV; (3) shape anomalies including LV basal narrowing and apical dilation; (4) myocardial alterations, including features of cardiomyopathy (i.e. non-compaction, hypertrophic) and myocardial fibrosis (both focal and diffuse)<sup>2 21 23 24</sup> (figures 5 and 6, online supplemental video 1 online supplemental file 5).

## Clinical manifestations and outcome in unoperated patients

EA is a rare disease, counting 1–2.6 cases per 200 000 of live births (<1% of congenital heart disease).<sup>1 25</sup> Clinical presentation after neonatal period has a more favourable outcome than cases diagnosed in earlier life.<sup>26</sup> Subjects growing up to adulthood exhibit less severe anatomical abnormalities and, due to high right chambers compliance to volume overload, are usually asymptomatic for a long time.<sup>25 27 28</sup> Mean age at diagnosis is around 14 years among children and 20–35 years in adults.<sup>25 26</sup> New York Heart Association (NYHA) class I or II characterises the majority of adult patients at diagnosis.<sup>28</sup> Arrhythmias are the most common clinical manifestation both in children and in adults, being a possible cause of NYHA class deterioration.<sup>25 28</sup> Typical electrocardiographic and arrhythmic profiles of patients with EA are detailed in online supplemental material (sections C and D, respectively).

Right-to-left shunt may lead to chronic hypoxia and exertional cyanosis, while rest cyanosis is more common during infancy.<sup>26</sup> Cerebrovascular embolic events, as assessed in around 8%–10% of cases, are attributable to either paradoxical embolization or atrial fibrillation occurrence.<sup>26 28</sup> Endocarditis is rare and favoured by device implantation or surgery.<sup>26 29</sup> Figure 5 illustrates distinctive EA symptoms and their physiological substrates.

Contemporary survival at 10 years from the diagnosis or at an age of 60 years old is assessed  $\geq 80\%$  among unoperated subjects.<sup>25 30</sup> Causes of death are principally related to HF (40%) and arrythmias (20%).<sup>28 30</sup> In a cohort of unoperated adults, sudden death (SD) had been reported in 23% of cases.<sup>28</sup> Clinical and instrumental features associated with unfavourable clinical outcome are reported in online supplemental table 2.

## MULTIDISCIPLINARY CLINICAL MANAGEMENT

A clinical follow-up is recommended at least yearly in patients with EA, although the monitoring strategy is tailored according to patient's specific features.<sup>9</sup> HF, arrhythmias and cyanosis are the main clinical manifestations with known prognostic impact in EA (online supplemental table 2) and can be tackled by a multidisciplinary approach of monitoring, prevention and treatment (figure 7). Sports and pregnancy are both practicable but require preliminary assessment (online supplemental material, section E). Current achievements and knowledge gaps in EA multidisciplinary management are summarised in online supplemental table 4.

#### **Drugs and HF treatment**

The effect of medical therapy on patients with EA has not yet been solidly investigated.  $^{31}$   $\beta\text{-blockers}$  and digoxin are used

View	Object of	Images	
	evaluation	Carpentier type A EA	Carpentier type C EA
PLAX	RA aRV fRV inflow <i>TV leaflets</i> : AL (*) adjacent to FW + SL (*) if IVS is seen + PL (*) if CS is seen	fRV RA CS	aRV * RA CS SC
PSAX	IAS RA aRV fRV ± Pas <i>TV leaflets</i> : PL (*) adjacent to FW AL (*) /SL (*) adjacent to Ao	fRV RA Ao LA	fRV RA Ao ASD LA
APICAL 4CH	IAS, RA, aRV, fRV, IVS, left chambers <i>TV leaflets</i> : SL (*) adjacent to IVS, AL (*) /PL (*) adjacent to FW	RA LA aRV LV	RA LA aRV * LV fRV
RIGHT OBLIQUE SUBXIFOID VIEW	RA aRV fRV inflow fRV apex RVOT <i>TV leaflets</i> : PL (*) adjacent to FW SL (*) /AL (*) contralateral	RA RVOT fRV	RA aRV RVOT. * fRV

**Figure 4** Main transthoracic echocardiographic views in EA. PLAX view was acquired with inferior tilt of the probe from conventional PLAX window. Right oblique subxifoid view was acquired with counterclockwise rotation of the transducer head from the four-chamber view. 4CH, fourchamber view; Ao, aorta; AL, anterior leaflet; aRV, atrialised right ventricle; ASD, atrial septal defect; CS, coronary sinus; EA, Ebstein's anomaly; fRV, functional right ventricle; FW, free wall; IAS, interatrial septum; IVS, interventricular septum; LA, left atrium; LV, left ventricle; Pas, pulmonary arteries; PL, posterior leaflet; PLAX, parasternal long-axis view; PSAX, parasternal short-axis view; RA, right atrium; RVOT, right ventricular outflow tract; SL, septal leaflet; TV, tricuspid valve leaflets.

to reduce tachycardia-induced ventricular dysfunction.<sup>31-33</sup> Class IC and III anti-arrhythmic drugs may help to control the arrhythmic burden, however, there is general agreement to avoid sotalol and amiodarone as long-term therapy due to their known proarrhythmic risk and side effects.<sup>32 33</sup> In case of accessory pathways (APs), the use of atrioventricular node blockers should be avoided. Oral anticoagulation may be appropriate in case of atrial fibrillation and right-to-left shunt.<sup>32</sup> Diuretics are used to relieve congestion, while a complete HF drug regimen may be justified in case of LV functional impairment.<sup>9 31</sup> Cardiac



**Figure 5** Clinical manifestations and pathophysiological substrates of Ebstein's anomaly. The interplay between arrhythmias and heart failure is highlighted. RA dilation promotes the occurrence of intra-atrial re-entries and the presence of accessory pathways may be the substrate for atrioventricular re-entries; aRV is vulnerable to trigger ventricular arrhythmias. Fast-conduced arrhythmias may contribute to ventricular dysfunction and reduced filling time. Adverse myocardial remodelling may enhance the arrhythmic substrate. Increased RA pressures favour right-to-left shunt in the presence of atrial communications, thus worsening hypoxia. Systemic embolisation is favoured by occurrence of atrial fibrillation or paradoxical thrombosis. Ao, aorta; ARV, anatomical right ventricle; aRV, atrialised right ventricle; LA, left atrium; L-R, left to right; LV, left ventricle; PA, pulmonary artery; R-L, right to left; RA, right atrium.

resynchronisation therapy can be applied in case of bundle branch block and either LV or RV dysfunction.<sup>32 34</sup> Both temporary mechanical cardiocirculatory supports implantation and heart transplantation had been performed in EA.<sup>29 35</sup> In endstage HF, a biventricular assistance device may be successfully implanted, while LV assistance alone showed to deteriorate TR and fRV function.<sup>36 37</sup> Pre-surgical LV dysfunction demonstrated an increased risk of death after EA repair compared with patients with preserved LV function, thus suggesting the need of a careful evaluation before excluding heart transplantation candidacy in selected cases.<sup>33</sup>

#### Ablation and life-threatening arrhythmias prevention

Catheter ablation (CAbl) reports a long-term success of about 80% for atrioventricular re-entrant tachycardia and cavotricuspid isthmus-dependent atrial flutter, up to 100% for intra-atrial re-entrant tachycardias, and 92% for ventricular tachycardias (VTs).<sup>38 39</sup> Principal challenges include an atrioventricular junction less demarcated than other anatomies, multiple and broad APs, abnormal activation potentials, RA and aRV dilation, and impaired catheter stability. Moreover, each patient with EA may undergo different arrhythmogenic substrates during a lifespan.<sup>38</sup> CAbl procedural steps are illustrated for an emblematic case of multiple APs in online supplemental figure 3.

In a large cohort study on subjects with or without surgical history, SD incidence was detected in up to 5.1 per 1000 patientyears.<sup>40</sup> VTs, pulmonary stenosis, haemoglobin > 15 g/dL, syncope and previous cardiac surgery on TV proved to be independent SD predictors.<sup>40</sup> Potential proarrhythmic effects of surgery include ventriculotomy and cut-and-sew Maze.<sup>40</sup> A preoperative electrophysiological study (EPS) may reduce post-surgical SD risk. Current guidelines recommend EPS in patients with known APs or a history of arrhythmias but an arrhythmogenic substrate in the absence of these criteria was demonstrated.<sup>8 9 41</sup> Moreover, SD occurrence showed only a weak association with APs, while a significant association was demonstrated with atrial tachycardias and an even greater with VTs, both spontaneous and induced.<sup>40</sup> Current indications to implantable cardiac defibrillator in EA are not defined, but features associated with SD include syncope, spontaneous or induced VTs, QRS complex duration  $\geq 180$  ms, QTc interval > 500 ms (online supplemental table 2).<sup>40</sup>

#### **Cardiac catheterization**

Interventional cardiac catheterization with closure of an interatrial communication (IAC) may alleviate cyanosis and prevent paradoxical embolisation.<sup>8</sup> <sup>9</sup> <sup>42</sup> A RA pressure  $\leq$ 18 mm Hg without signs of low cardiac output is considered a safe cut-off for IAC closure. Right-to-left shunt in EA is favoured by the streaming of TR jet rather than right-sided filling pressures, which are elevated mostly in cases of RVOT obstruction.<sup>42</sup>

Transcatheter IAC closure is a valuable option in selected patients, having proved to be associated with increased pulse oxygen saturation and exercise tolerance.<sup>8</sup> <sup>9</sup> The evidence that increased haemoglobin levels are a SD risk factor in EA



**Figure 6** Structural and functional cardiac alterations in Ebstein's anomaly (A) and changes after cone repair surgery (B). Also, a cine SSFP CMR sequence (horizontal long-axis view at end-diastole) is reported in the same patient before (A) and after cone repair (B). Ao, aorta; aRV, atrialised right ventricle; CMR, cardiovascular magnetic resonance; fRV, functional right ventricle; fSV, forward stroke volume; IVS, interventricular septum; LA, left atrium; LV, left ventricle; PA, pulmonary artery; RA, right atrium; RV, right ventricle; SSFP, steady-state free precession; TR, tricuspid regurgitation.

questioned if the closure of IAC itself may contribute to improve outcome in EA. The positive impact on functional capacity demonstrated after surgery may be at least partially related to IAC closure, while robust data focusing on surgical outcome in patients without IAC are lacking.<sup>43</sup>

## Surgery

Monocusp reconstruction for surgical treatment of EA had been used for many years (online supplemental table 5).<sup>44</sup> Nonetheless, there is nowadays a general consensus on adopting a more anatomical form of repair, described by da Silva *et al*<sup>45</sup> in 2007 (figure 8, online supplemental videos 4 and 5).

The concept of da Silva's cone repair (CR) is to perform a surgical delamination of all the rescuable leaflets in order to obtain a 360° TV annulus in anatomical position.<sup>45</sup> Plication, or triangular resection, of both the dilated aRV and atrioventricular junction is often necessary to adapt the cone-shaped neo valve to the anatomical annulus (figure 8). In this process, caution should be paid in avoiding right coronary artery damage (figures 2 and 8). During the neo-valve attachment, the suture line of the septal region is generally performed just below the anatomical annulus in order to avoid conduction tissue injuries. Such manoeuvre renders the septal area particularly vulnerable to post-surgical dehiscence, as shown in figure 2.

In case of inadequate fRV function, impossible weaning from cardiopulmonary by-pass or neo-valve stenosis, an associated bidirectional superior cavo-pulmonary anastomosis is generally performed ('one-and-a-half repair').<sup>46</sup> Glenn anastomosis showed to enhance LV filling and decrease fRV preload, thus reducing postoperative peripheral congestion.<sup>46</sup> When fRV size is reduced, a fenestrated rather than complete closure of

the atrial septal defect can be considered.<sup>9</sup> Possible additional surgical modifications include TV annuloplasty, pericardial patch enlargement of AL, and the so-called 'Sebening stitch' to mobilise the anterior papillary muscle toward the IVS, improving coaptation.

CR proved to be feasible in most of EA anatomies, as shown by online supplemental videos 6 and 7. The presence of a great functional TV rotation angle or fRV dilation showed to increase the probability of surgical breakdown (online supplemental table 3). In cases of extended deficit of delamination involving leaflets other than septal, the rescuable tissue may be scant and TV replacement might be considered.<sup>47</sup> Bioprosthetic rather than mechanical valves are preferred thanks to their acceptable durability, no need for anticoagulants, and the possibility of subsequent transcatheter 'valve-in-valve' procedures.

#### Clinical outcome in operated patients

When compared with previous repair techniques, CR showed better results in terms of residual TR, freedom of re-operation and life expectancy.<sup>45 48</sup> Advantages of CR include growth potential and durability of the native tissue, no need for long-term anticoagulation therapy, and a more physiological TV and RV geometry.<sup>48</sup> CR demonstrated a favourable impact on RV and LV remodelling (figure 6), patient's clinical status and exercise capacity.<sup>23 29 48 49</sup> LV SV and peak oxygen consumption are parameters associated with adverse outcome in unoperated patients that showed to improve after CR. Nonetheless, biven-tricular EF has still shown no significant changes postoperatively, possibly due to the preload dependency.<sup>12 23 29 49</sup> Online supplemental table 3 provides an overview on the existing identified predictors of post-surgical outcomes in EA.



**Figure 7** Possible outcome modifiers and monitoring strategy for the key clinical manifestations of Ebstein' anomaly, namely heart failure, arrhythmias and cyanosis. BNP, brain-natriuretic peptide; CPET, cardiopulmonary exercise test; EPS, electrophysiological study; Hb, haemoglobin; Hct, haematocrit; IAC, interatrial communication; NYHA, New York Heart Association class; O2, oxygen; spO2, peripheral oxygen saturation; TR, tricuspid regurgitation; VE/VCO2, minute ventilation/carbon dioxide production; VO2, oxygen consumption; WPW, Wolf-Parkinson-White pattern.

Current indication to surgical intervention is severe TR with symptoms or, in the absence of symptoms, with progression in either right-sided heart dilation or fRV systolic dysfunction.<sup>8</sup> <sup>9</sup> However, there is evidence that aerobic capacity is affected even in asymptomatic children and deteriorates rapidly before adulthood.<sup>50</sup> Furthermore, without symptoms, a long 'wait and see' may be needed to demonstrate right-sided heart disease progression.<sup>28</sup> <sup>51</sup> In younger patients, cumulative data suggest better structural results and more effective clinical impact of surgical repair than in older adults.<sup>443 47 51</sup> Probability of re-operation or need for TV prosthetic replacement is greater with increasing age at intervention.<sup>451</sup> Furthermore, exercise capacity and functional class showed to be adequate in patients who received a repair during childhood or adolescence, while not every patient operated older than 50 years revealed a clinical improvement.<sup>43 47 51</sup>

The latter patient subset showed lower long-term survival than younger patients and lower life expectancy compared with agematched general population.<sup>43 47 51</sup>

Nonetheless, the surgical mortality risk for younger patients is not negligible even in experienced centres and, in the absence of randomized control studies, whether an early operation may effectively prevent complications of EA natural history is still debated.  $^{29}$   $^{47}$   $^{52}$ 

# CONCLUSIONS

EA diagnosis or diagnostic suspect should guide patient's referral to a specialised multidisciplinary team. EA spectrum of heterogeneous anatomical and clinical features requires a patient-tailored monitoring strategy. Large cohort studies are needed to assess



**Figure 8** Cone repair surgery is realised through a median sternotomy in cardiopulmonary by-pass with standard aortic and bicaval cannulation, left vent and cardioplegic cardiac arrest. After careful inspection and marking of the coronary arteries' anatomy (A), transverse RA incision is performed in the direction of the cavotricuspid isthmus. After a complete detachment and mobilisation of the delamination defects (B), part of the aRV is plicated or resected (C), and the neo valve, generally slightly rotated clockwise, is sutured into the anatomical annulus (D). The result is a cone-shaped valve with the vertex fixed at the RV apex (E); the valve is tested for competency (F), and then, if needed, stabilised with ring annuloplasty (G). RA, right atrium; RV, right ventricle.

the impact of medical treatment and to identify the best interventional approach, which should rely on time of presentation to medical attention as well as on indicators effectively correlating with clinical outcome.

#### Author affiliations

<sup>1</sup>Pediatric and Adult Congenital Disease Heart Centre, IRCCS Policlinico San Donato, San Donato Milanese, Italy

<sup>2</sup>European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart, Amsterdam, Netherlands

<sup>3</sup>Arrhythmia and Electrophysiology Department, IRCCS Policlinico San Donato, San Donato Milanese, Italy

<sup>4</sup>Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, Milano, Italy <sup>5</sup>3D and Computer Simulation Laboratory, IRCCS Policlinico San Donato, San Donato Milanese, Italy

<sup>6</sup>Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milano, Italy

<sup>7</sup>Department of Congenital Cardiac Surgery, IRCCS Policlinico San Donato, San Donato Milanese, Italy

Twitter Giulia Pasqualin @g\_pasqualin and Cecilia Marcolin @marcolin.cecilia@ hsr.it

Acknowledgements This work was partially supported by Ricerca Corrente funding from Italian Ministry of Health to IRCCS Policlinico San Donato. The authors are thankful to Professor Ashwin Prakash (Boston Children's Hospital, Boston, Massachusetts, USA), Professor Eustachio Agricola, Dr Francesco Ancona, Dr Stefano Stella and Dr Giacomo Ingallina (Cardiovascular Imaging Unit, Cardio-Thoracic-Vascular Department, IRCCS San Raffaele Scientific Institute, Milan, Italy) for their valuable support in providing part of the cardiovascular imaging enclosed in the present review.

Collaborators Not applicable.

**Contributors** GP conceptualised the review and drafted the initial manuscript, coordinating the revision process. MC, GC, EM, CP and AG contributed to sections of the review and implemented content according to the specific expertise of each author. GP, MC, CP, FS and AG critically reviewed the intellectual content of the manuscript. GP, CM, AB and FS designed, drafted and revised all figures, tables and videos. AG contributed to funding acquisition. All authors revised the final version of the review, reading and approving the submitted version.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Commissioned; externally peer reviewed.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

#### ORCID iDs

Giulia Pasqualin http://orcid.org/0000-0002-3362-4501 Massimo Chessa http://orcid.org/0000-0001-7432-4815 Giuseppe Ciconte http://orcid.org/0000-0001-7886-5467 Emanuele Micaglio http://orcid.org/0000-0002-8298-7800

# Review

Carlo Pappone http://orcid.org/000-0002-0901-6135 Francesco Sturla http://orcid.org/0000-0001-7317-304X

#### REFERENCES

- Dearani JA, Danielson GK. Congenital heart surgery nomenclature and database project: Ebstein's anomaly and Tricuspid valve disease. *Ann Thorac Surg* 2000;69(4 Suppl):S106–17.
- 2 Attenhofer Jost CH, Connolly HM, O'Leary PW, *et al*. Left heart lesions in patients with Ebstein anomaly. *Mayo Clin Proc* 2005;80:361–8.
- 3 Lamers WH, Virágh S, Wessels A, *et al*. Formation of the Tricuspid valve in the human heart. *Circulation* 1995;91:111–21.
- 4 Hughes ML, Bonello B, Choudhary P, et al. A simple measure of the extent of Ebstein valve rotation with cardiovascular magnetic resonance gives a practical guide to feasibility of surgical cone reconstruction. J Cardiovasc Magn Reson 2019;21:34.
- 5 Anderson KR, Lie JT. The right ventricular myocardium in Ebstein's anomaly: a morphometric histopathologic study. *Mayo Clin Proc* 1979;54:181–4.
- 6 Attenhofer Jost CH, Edmister WD, Julsrud PR, et al. Prospective comparison of echocardiography versus cardiac magnetic resonance imaging in patients with Ebstein's anomaly. Int J Cardiovasc Imaging 2012;28:1147–59.
- 7 Gussenhoven EJ, Stewart PA, Becker AE, *et al*. Offsetting" of the septal Tricuspid leaflet in normal hearts and in hearts with Ebstein's anomaly. *Am J Cardiol* 1984;54:172–6.
- 8 Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: executive summary: A report of the American college of cardiology/American heart Association task force on clinical practice guidelines. J Am Coll Cardiol 2019;73:1494–563.
- 9 Baumgartner H, De Backer J, Babu-Narayan SV. ESC guidelines for the management of adult congenital heart disease. *Eur Heart J* 2020;41:4153–4.
- 10 Celermajer DS, Cullen S, Sullivan ID, et al. Outcome in neonates with Ebstein's anomaly. J Am Coll Cardiol 1992;19:1041–6.
- 11 Hösch O, Sohns JM, Nguyen T-T, et al. The total right/left-volume index: a new and simplified cardiac magnetic resonance measure to evaluate the severity of Ebstein anomaly of the Tricuspid valve: a comparison with heart failure markers from various modalities. Circ Cardiovasc Imaging 2014;7:601–9.
- 12 Rydman R, Shiina Y, Diller G-P, et al. Major adverse events and atrial tachycardia in Ebstein's anomaly predicted by cardiovascular magnetic resonance. *Heart* 2018;104:37–44.
- 13 Tobler D, Yalonetsky S, Crean AM, et al. Right heart characteristics and exercise parameters in adults with Ebstein anomaly: new perspectives from cardiac magnetic resonance imaging studies. Int J Cardiol 2013;165:146–50.
- 14 Steinmetz M, Broder M, Hösch O, et al. Atrio-ventricular deformation and heart failure in Ebstein's anomaly - A cardiovascular magnetic resonance study. Int J Cardiol 2018;257:54–61.
- 15 Ciepłucha A, Trojnarska O, Kociemba A, et al. Clinical aspects of myocardial fibrosis in adults with Ebstein's anomaly. *Heart Vessels* 2018;33:1076–85.
- 16 Prota C, Di Salvo G, Sabatino J, et al. Prognostic value of echocardiographic parameters in pediatric patients with Ebstein's anomaly. Int J Cardiol 2019;278:76–83.
- 17 Baessato F, Furtmüller C, Shehu N, et al. Detection of early signs of right ventricular systolic impairment in Unoperated Ebstein's anomaly by cardiac magnetic resonance feature tracking. Cardiovasc Diagn Ther 2022;12:278–88.
- 18 Yalonetsky S, Tobler D, Greutmann M, et al. Cardiac magnetic resonance imaging and the assessment of Ebstein anomaly in adults. Am J Cardiol 2011;107:767–73.
- 19 Egidy Assenza G, Valente AM, Geva T, *et al*. QRS duration and QRS fractionation on surface electrocardiogram are markers of right ventricular dysfunction and Atrialization in patients with Ebstein anomaly. *Eur Heart J* 2013;34:191–200.
- 20 Park S-J, Chung S, On YK, et al. Fragmented QRS complex in adult patients with Ebstein anomaly and its association with arrhythmic risk and the severity of the anomaly. *Circ Arrhythm Electrophysiol* 2013;6:1148–55.
- 21 Goleski PJ, Sheehan FH, Chen SSM, et al. The shape and function of the left ventricle in Ebstein's anomaly. Int J Cardiol 2014;171:404–12.
- 22 Inai K, Nakanishi T, Mori Y, et al. Left ventricular diastolic dysfunction in Ebstein's anomaly. Am J Cardiol 2004;93:255–8.
- 23 Ibrahim M, Tsang VT, Caruana M, et al. Cone reconstruction for Ebstein's anomaly: patient outcomes, biventricular function, and cardiopulmonary exercise capacity. J Thorac Cardiovasc Surg 2015;149:1144–50.
- 24 Yang D, Li X, Sun J-Y, et al. Cardiovascular magnetic resonance evidence of myocardial fibrosis and its clinical significance in adolescent and adult patients with Ebstein's anomaly. J Cardiovasc Magn Reson 2018;20:69.

- 25 Luu Q, Choudhary P, Jackson D, et al. Ebstein's anomaly in those surviving to adult life - a single centre experience. *Heart Lung Circ* 2015;24:996–1001.
- 26 Herrera-Bello H, Ávila-Vanzzini N, Fritche-Salazar JF, et al. Clinical spectrum and longterm outcome of 183 cases of Ebstein's anomaly. experience of Mexican population. Arch Med Res 2020;51:336–42.
- 27 Geerdink LM, Delhaas T, Helbing WA, et al. Paediatric Ebstein's anomaly: how clinical presentation predicts mortality. Arch Dis Child 2018;103:859–63.
- 28 Attie F, Rosas M, Rijlaarsdam M, et al. The adult patient with Ebstein anomaly. outcome in 72 Unoperated patients. *Medicine (Baltimore)* 2000;79:27–36.
- 29 Brown ML, Dearani JA, Danielson GK, et al. The outcomes of operations for 539 patients with Ebstein anomaly. J Thorac Cardiovasc Surg 2008;135:1120–36,
- 30 Pornprasertchai V, Vijarnsorn C, Kanjanauthai S, et al. Contemporary outcomes and mortality risks of Ebstein anomaly: A single-center experience in Thailand. Congenit Heart Dis 2019;14:619–27.
- 31 Schultz K, Haeffele CL. Heart failure in the adult Ebstein patient. *Heart Fail Rev* 2020;25:623–32.
- 32 Hernández-Madrid A, Paul T, Abrams D, et al. Arrhythmias in congenital heart disease: a position paper of the European heart rhythm Association (EHRA). In: Association for European Paediatric and Congenital Cardiology (AEPC), and the European Society of Cardiology (ESC) Working Group on Grown-up Congenital heart disease, endorsed by HRS, PACES, APHRS, and SOLAECE . Europace, 2018: 20. 1719–53.
- 33 Brown ML, Dearani JA, Danielson GK, et al. Effect of operation for Ebstein anomaly on left ventricular function. *The American Journal of Cardiology* 2008;102:1724–7.
- 34 Janoušek J, Kovanda J, Ložek M, et al. Cardiac Resynchronization therapy for treatment of chronic Subpulmonary right ventricular dysfunction in congenital heart disease. Circ Arrhythm Electrophysiol 2019;12:e007157.
- 35 Cabezón G, Stephanenko A, Redondo A, et al. Impella RP in Ebstein disease as a bridge to heart transplant. JACC Cardiovasc Interv 2021;14:e57–60.
- 36 Selzman CH, Desjardins G, Patel AN, et al. Complications associated with the use of left ventricular assist device therapy in an adult patient with Ebstein's anomaly. Ann Thorac Surg 2012;93:297–9.
- 37 Das BB, Chrisant M, Lavandosky G, et al. An adolescent with left ventricular Noncompaction and Ebstein anomaly presenting with advanced heart failure: discharge from hospital with a biventricular assist device. J Pediatr 2018;202:304–10.
- 38 Roten L, Lukac P, DE Groot N, et al. Catheter ablation of arrhythmias in Ebstein's anomaly: a multicenter study. J Cardiovasc Electrophysiol 2011;22:1391–6.
- 39 Moore JP, Shannon KM, Gallotti RG, et al. Catheter ablation of ventricular arrhythmia for Ebstein's anomaly in Unoperated and post-surgical patients. JACC Clin Electrophysiol 2018;4:1300–7.
- 40 Attenhofer Jost CH, Tan NY, Hassan A, *et al*. Sudden death in patients with Ebstein anomaly. *Eur Heart J* 2018;39:1970–1977a.
- 41 Shivapour JKL, Sherwin ED, Alexander ME, *et al*. Utility of preoperative Electrophysiologic studies in patients with Ebstein's anomaly undergoing the cone procedure. *Heart Rhythm* 2014;11:182–6.
- 42 Silva M, Teixeira A, Menezes I, et al. Percutaneous closure of atrial right-to-left shunt in patients with Ebstein's anomaly of the Tricuspid valve. EuroIntervention 2012;8:94–7.
- 43 Egbe A, Miranda W, Connolly H, et al. Haemodynamic determinants of improved aerobic capacity after Tricuspid valve surgery in Ebstein anomaly. *Heart* 2021;107:1138–44.
- 44 Carpentier A, Chauvaud S, Macé L, et al. A new Reconstructive operation for Ebstein's anomaly of the Tricuspid valve. J Thorac Cardiovasc Surg 1988;96:92–101.
- 45 da Silva JP, Baumgratz JF, da Fonseca L, *et al*. The cone reconstruction of the Tricuspid valve in Ebstein's anomaly. *J Thorac Cardiovasc Surg* 2007;133:215–23.
- 46 Quinonez LG, Dearani JA, Puga FJ, et al. Results of the 1.5-ventricle repair for Ebstein anomaly and the failing right ventricle. J Thorac Cardiovasc Surg 2007;133:1303–10.
- 47 Boston US, Dearani JA, O'Leary PW, et al. Tricuspid valve repair for Ebstein's anomaly in young children: a 30-year experience. Ann Thorac Surg 2006;81:690–5;
- 48 Burri M, Mrad Agua K, Cleuziou J, et al. Cone versus conventional repair for Ebstein's anomaly. J Thorac Cardiovasc Surg 2020;160:1545–53.
- 49 Neijenhuis RML, Tsang VT, Marek J, et al. Cone reconstruction for Ebstein anomaly: late biventricular function and possible remodeling. J Thorac Cardiovasc Surg 2021;161:1097–108.
- 50 Kipps AK, Graham DA, Lewis E, et al. Natural history of exercise function in patients with Ebstein anomaly: A serial study. Am Heart J 2012;163:486–91.
- 51 Attenhofer Jost CH, Connolly HM, Scott CG, et al. Outcome of cardiac surgery in patients 50 years of age or older with Ebstein anomaly: survival and functional improvement. J Am Coll Cardiol 2012;59:2101–6.
- 52 Anderson HN, Dearani JA, Said SM, et al. Cone reconstruction in children with Ebstein anomaly: the Mayo clinic experience. *Congenit Heart Dis* 2014;9:266–71.